These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39353360)

  • 1. Brusatol improves the efficacy of sorafenib in Huh7 cells via ferroptosis resistance dependent Nrf2 signaling pathway.
    Liu X; Liu T; Zhou Z; Bian K; Qiu C; Zhang F
    Biochem Biophys Res Commun; 2024 Nov; 734():150762. PubMed ID: 39353360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.
    Liu X; Zhang F; Fan Y; Qiu C; Wang K
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113107. PubMed ID: 39276458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
    Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
    Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
    Hu Y; Luo Z; Cai S; Xie Q; Zheng S
    Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
    Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K
    Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
    Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
    Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
    [No Abstract]   [Full Text] [Related]  

  • 7. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Elkateb AS; Nofal S; Ali SA; Atya HB
    Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
    Yu X; He Z; Wang Z; Ke S; Wang H; Wang Q; Li S
    Exp Cell Res; 2024 May; 438(2):114053. PubMed ID: 38663476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
    Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
    Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3.
    Wan Y; Cheng J; Gan D; He J; Chen A; Ma J; Li Y; Wang X; Ran J; Chen D; Li J
    Chem Biol Drug Des; 2024 Jun; 103(6):e14565. PubMed ID: 38862254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
    PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression.
    Li Z; Kim W; Utturkar S; Yan B; Lanman NA; Elzey BD; Kazemian M; Yeo Y; Andrisani O
    Cell Death Dis; 2024 Aug; 15(8):583. PubMed ID: 39122708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
    Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
    J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis.
    Tang Q; Wang Y; Yan B; Zhang J; Wang T; Fang Y; Ye Z; Zhang N; Zhang N; Wu Z; Fan H; Lyu Y; Liu X; Wu R
    ACS Nano; 2024 Oct; 18(43):29804-29819. PubMed ID: 39431335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy.
    Du Y; Zhou Y; Yan X; Pan F; He L; Guo Z; Hu Z
    Cell Death Differ; 2024 Apr; 31(4):431-446. PubMed ID: 38418695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
    Murakami Y; Sugiyama K; Ebinuma H; Nakamoto N; Ojiro K; Chu PS; Taniki N; Saito Y; Teratani T; Koda Y; Suzuki T; Saito K; Fukasawa M; Ikeda M; Kato N; Kanai T; Saito H
    BMC Cancer; 2018 Jun; 18(1):680. PubMed ID: 29940898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway.
    Lin Y; Chen K; Zhu M; Song W; Wu G; Pan A
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; 397(10):7697-7710. PubMed ID: 38709266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.